Baseline Values and Sotalol-Induced Changes of Ventricular Repolarization Duration, Heterogeneity, and Instability in Patients With a History of Drug-Induced Torsades de Pointes

被引:23
|
作者
Couderc, Jean-Philippe [1 ]
Kaab, Stefan [2 ]
Hinterseer, Martin [2 ]
McNitt, Scott [1 ]
Xia, Xiaojuan [1 ]
Fossa, Anthony [3 ]
Beckmann, Britt M. [2 ]
Polonsky, Slava [1 ]
Zareba, Wojciech [1 ]
机构
[1] Univ Rochester, Med Ctr, Dept Cardiol, Heart Res Follow Up Program, Rochester, NY 14642 USA
[2] Univ Munich, Klinikum Grosshadern, Dept Med 1, D-8000 Munich, Germany
[3] iCardiac Technol Inc, Rochester, NY USA
关键词
QT interval; Torsades de Pointes; electrocardiogram; sotalol; LONG-QT-SYNDROME; ATRIAL-FIBRILLATION; I-KR; VARIABILITY; INTERVAL; PROARRHYTHMIA; TRIANGULATION; PROLONGATION; TACHYCARDIA; RECORDINGS;
D O I
10.1177/0091270008325927
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The authors investigated whether computerized parameters quantifying ventricular repolarization delay, heterogeneity, and instability characterize individuals who developed drug-induced Torsades de Pointes. Assessing an individual's propensity to Torsades de Pointes when exposed to a QT-prolonging drug is challenging because baseline QT prolongation has limited predictive value. Five-minute digital 12-lead electrocardiograms were acquired at baseline and after a sotalol challenge in 16 patients who had a history of Torsades de Pointes in the context of a QT-prolonging drug and 17 patients who did not have such history. Computerized measurements of QTc, T peak to T end intervals (TpTe), TpTe/QTc, and QT variability were implemented, and novel quantifiers of ventricular repolarization heterogeneity from the early (ERD) and late (LRD) part of the T wave were investigated. Compared with electrocardiograms of patients without a history of Torsades de Pointes, the baseline electrocardiograms of patients with a history of Torsades de Pointes had a longer QTc and an increased repolarization heterogeneity of the early part of the T wave (ERD30%: 44 +/- 13 vs 35 +/- 8 ms, P = .02). On sotalol, the electrocardiograms from individuals with Torsades de Pointes revealed a delay of the terminal part of the T wave that was not present in patients without Torsades de Pointes (TpTe: 27 +/- 40 vs -2 +/- 21 ms, P = .02; LRD70%: 20 +/- 29 vs 2 +/- 4 ms, P = .04). Results suggest that the electrocardiogram abnormalities characterizing patients with a history of Torsades de Pointes are (1) an increased repolarization heterogeneity at baseline and (2) a sotalol-induced prolongation of the terminal part of the T wave.
引用
收藏
页码:6 / 16
页数:11
相关论文
共 50 条
  • [31] Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs
    Thomsen, MB
    Verduyn, SC
    Stengl, M
    Beekman, JDM
    de Pater, G
    van Opstal, J
    Volders, PGA
    Vos, MA
    CIRCULATION, 2004, 110 (16) : 2453 - 2459
  • [32] QTc compared to JTc for monitoring drug-induced repolarization changes in the setting of ventricular pacing
    Tsai, Shane F.
    Houmsse, Mahmoud
    Dakhil, Barrah
    Augostini, Ralph
    Hummel, John D.
    Kalbfleisch, Steven J.
    Liu, Zhengou
    Love, Charles
    Rhodes, Troy
    Tyler, Jaret
    Weiss, Raul
    Hamam, Ismail
    Winner, Marshall
    Daoud, Emile G.
    HEART RHYTHM, 2014, 11 (03) : 485 - 491
  • [33] The possible role of propofol in drug-induced torsades de pointes: A real-world single-center analysis
    Abrich, Victor A.
    Ramakrishna, Harish
    Mehta, Arjun
    Mookadam, Farouk
    Srivathsan, Komandoor
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 232 : 243 - 246
  • [34] Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?
    Jorge Romero
    Samuel H. Baldinger
    David Goodman-Meza
    Krysthel Engstrom
    Carolina R. Valencia
    Anjani Golive
    Francisco Medrano
    Sabarivinoth Rangasamy
    Mohammed Makkiya
    John D. Fisher
    Jay Gross
    Andrew Krumerman
    Soo Kim
    Mario J. Garcia
    Luigi Di Biase
    Kevin J Ferrick
    Journal of Interventional Cardiac Electrophysiology, 2016, 45 : 37 - 45
  • [35] The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes
    Behr, Elijah R.
    January, Craig
    Schulze-Bahr, Eric
    Grace, Andrew A.
    Kaeaeb, Stefan
    Fiszman, Monica
    Gathers, Shaniece
    Buckman, ShaAvhree
    Youssef, Ashraf
    Pirmohamed, Munir
    Roden, Dan
    EUROPEAN HEART JOURNAL, 2013, 34 (26) : 1958 - 1963
  • [36] International life sciences institute (health and environmental sciences institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes
    Bass, A. S.
    Darpo, B.
    Breidenbach, A.
    Bruse, K.
    Feldman, H. S.
    Garnes, D.
    Hammond, T.
    Haverkamp, W.
    January, C.
    Koerner, J.
    Lawrence, C.
    Leishman, D.
    Roden, D.
    Valentin, J. P.
    Vos, M. A.
    Zhou, Y-Y
    Karluss, T.
    Sager, P.
    BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (07) : 1491 - 1501
  • [37] Global Optimization of Ventricular Myocyte Model to Multi-Variable Objective Improves Predictions of Drug-Induced Torsades de Pointes
    Krogh-Madsen, Trine
    Jacobson, Anna F.
    Ortega, Francis A.
    Christini, David J.
    FRONTIERS IN PHYSIOLOGY, 2017, 8
  • [38] Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts
    Sugiyama, A.
    BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (07) : 1528 - 1537
  • [39] Progesterone pretreatment reduces the incidence of drug-induced torsades de pointes in atrioventricular node-ablated isolated perfused rabbit hearts
    Tisdale, James E.
    Jaynes, Heather A.
    Overholser, Brian R.
    Sowinski, Kevin M.
    Kovacs, Richard J.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2019, 30 (06) : 941 - 949
  • [40] Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes
    Ramirez, A. H.
    Shaffer, C. M.
    Delaney, J. T.
    Sexton, D. P.
    Levy, S. E.
    Rieder, M. J.
    Nickerson, D. A.
    George, A. L., Jr.
    Roden, D. M.
    PHARMACOGENOMICS JOURNAL, 2013, 13 (04) : 325 - 329